Cyclofemina 25mg 5 mg (Injection) Medroxiprogesterona, Estradiol
THIS IS THE BRAND MEDICATION FROM CARNOT
The estrogen component of combined hormonal contraceptives may induce a decrease in the amount of breast milk. Although not stated if they can cause adverse effects on the infant, not recommended for use during
breastfeeding in the first 6 months.
ADVERSE REACTIONS : There has been a low incidence of side effects reported more frequently in the initial cycles of hormonal contraceptive therapy, such as bleeding or spotting, alteration of normal bleeding pattern rarely reaches amenorrhea, nausea, vomiting, headache and slight alteration of body weight.
Adverse effects such as acne, hirsutism, breast tenderness, breast pain, metabolic changes, liver, irritability, have been reported in connection with the implementation of CYCLOFEMINA *.
DRUG INTERACTIONS AND OTHER GENDER : CYCLOFEMINA *, like any other oral or parenteral hormonal contraceptives may decrease the antidepressant response to tricyclics and increase the frequency of adverse
effects by the simultaneous use of compounds with estrogen, anticonvulsants such as phenobarbital, primidone, carbamazepine and phenytoin, induce liver enzymes may reduce the contraceptive effect. TB employing as rifampicin or of certain antibiotics such as ampicillin, can also decrease the contraceptive effect, so that precaution is suggested as a method also used nonhormonal (barrier) * CYCLOFEMINA when administered concomitantly with these drugs.
DOSAGE AND DIRECTIONS FOR USE : The first injection of CYCLOFEMINA * must be applied between the 1st. and 5th. days of the menstrual cycle, counting the first day of menstruation as the first day of the cycle. To ensure 100% contraceptive effectiveness, the second injection and subsequent be applied every 30 days. In special cases may be applied 3 days after maximum.
The user must be informed after the first injection, menstruation happen applied 15 days after this. Subsequently be submitted each month.
In non-breastfeeding postpartum patients may be started at six weeks post-abortion patients in the first seven days.
ADMINISTRATION : Each intramuscular injection should be applied in deeply, preferably in the gluteal region (pump).
PRESENTATIONS : 0.5 ml ampoule.
Box with a vial with 0.5 ml of suspension and informative annex.